Difference between revisions of "Olanzapine (Zyprexa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Atypical antipsychotic with antiemetic properties, likely through its effect on dopamine receptors. No known antineoplastic properties. | Atypical antipsychotic with antiemetic properties, likely through its effect on dopamine receptors. No known antineoplastic properties. | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2017-12-25: new additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). | ||
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Zyprexa | *'''Brand name:''' Zyprexa | ||
Revision as of 01:19, 9 June 2023
Mechanism of action
Atypical antipsychotic with antiemetic properties, likely through its effect on dopamine receptors. No known antineoplastic properties.
History of changes in PMDA indication
- 2017-12-25: new additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.).
Also known as
- Brand name: Zyprexa